First Time Loading...

Inhibrx Inc
NASDAQ:INBX

Watchlist Manager
Inhibrx Inc Logo
Inhibrx Inc
NASDAQ:INBX
Watchlist
Price: 34.35 USD 0.62% Market Closed
Updated: May 29, 2024

Inhibrx Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inhibrx Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Inhibrx Inc
NASDAQ:INBX
Capital Expenditures
-$4.6m
CAGR 3-Years
-50%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$795m
CAGR 3-Years
3%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
-$581m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$998m
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$464.7m
CAGR 3-Years
-14%
CAGR 5-Years
-41%
CAGR 10-Years
-25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$809.1m
CAGR 3-Years
-13%
CAGR 5-Years
-16%
CAGR 10-Years
-15%

See Also

What is Inhibrx Inc's Capital Expenditures?
Capital Expenditures
-4.6m USD

Based on the financial report for Dec 31, 2023, Inhibrx Inc's Capital Expenditures amounts to -4.6m USD.

What is Inhibrx Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-26%

Over the last year, the Capital Expenditures growth was -566%. The average annual Capital Expenditures growth rates for Inhibrx Inc have been -50% over the past three years , -26% over the past five years .